CO5690561A2 - Administracion oral de acido [2-(8,9-dioxo-2,6-diazabiciclo[5.2.0]non-1(7)-en-2-il)alquil]fosfonico y derivados - Google Patents
Administracion oral de acido [2-(8,9-dioxo-2,6-diazabiciclo[5.2.0]non-1(7)-en-2-il)alquil]fosfonico y derivadosInfo
- Publication number
- CO5690561A2 CO5690561A2 CO06037154A CO06037154A CO5690561A2 CO 5690561 A2 CO5690561 A2 CO 5690561A2 CO 06037154 A CO06037154 A CO 06037154A CO 06037154 A CO06037154 A CO 06037154A CO 5690561 A2 CO5690561 A2 CO 5690561A2
- Authority
- CO
- Colombia
- Prior art keywords
- group
- carbon atoms
- aryl
- hydrogen
- branched
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
1.- Una forma farmacéutica de dosificación sólida, que comprende:al menos un compuesto de fórmula (I) o una sal farmacéuticamente aceptable del mismo: en la que:R1 es hidrógeno, un grupo alquilo C1 a C6, un grupo acilo C2 a C7, un grupo alcanosulfonilo C1 a C6 o un grupo aroílo C6 a C14;A es alquilenilo de 1 a 4 átomos de carbono o alquenilenilo de 2 a 4 átomos de carbono;R2 y R3 se seleccionan independientemente entre hidrógeno,con la condición de que al menos uno de R2 y R3 sea distinto de hidrógeno;R4 y R5 se seleccionan independientemente entre hidrógeno, un grupo alquilo C1 a C4, un grupo arilo C5 a C7, un grupo aralquilo C6 a C15 con 5 a 7 átomos de carbono en el anillo arilo, un grupo alquenilo C2 a C7 o grupo alquinilo C2 a C7 o R4 y R5 pueden formar juntos un anillo espiro C3 a C8 carbocíclico;R6 es un grupo alquilo C1 a C12 lineal o ramificado, un grupo alquenilo o alquinilo C2 a C7 lineal o ramificado, un grupo arilo C5 a C13, un grupo aralquilo C6 a C21 con 5 a 13 átomos de carbono en el resto arilo; un grupo heteroarilo de 5 a 13 miembros, un grupo heteroalquilo de 6 a 21 miembros con 5 a 13 miembros en el resto heteroarilo, un grupo cicloalquilo C4 a C8, un grupo cicloalquilalquilo C5 a C16 con 4 a 8 átomos de carbono en el anillo cicloalquilo;R7 y R8 se seleccionan independientemente entre hidrógeno, un grupo alquilo C1 a C12 lineal o ramificado, un grupo alquenilo o alquinilo C2 a C7 lineal o ramificado, un grupo arilo C5 a C13, un grupo aralquilo C6 a C21 con 5 a 13 átomos de carbono en el resto arilo, un grupo heteroarilo de 5 a 13 miembros, un grupo heteroarilo de 6 a 21 miembros con 5 a 13 miembros en el resto heteroarilo o R7 y R8 pueden formar juntos un grupo cicloalquilo o ...
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51156003P | 2003-10-15 | 2003-10-15 | |
US10/961,871 US20050142192A1 (en) | 2003-10-15 | 2004-10-08 | Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5690561A2 true CO5690561A2 (es) | 2006-10-31 |
Family
ID=34704145
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO06037154A CO5690561A2 (es) | 2003-10-15 | 2006-04-19 | Administracion oral de acido [2-(8,9-dioxo-2,6-diazabiciclo[5.2.0]non-1(7)-en-2-il)alquil]fosfonico y derivados |
Country Status (13)
Country | Link |
---|---|
US (1) | US20050142192A1 (es) |
EP (1) | EP1682151A1 (es) |
JP (1) | JP2007509055A (es) |
KR (1) | KR20070029114A (es) |
AU (1) | AU2004281806A1 (es) |
BR (1) | BRPI0415432A (es) |
CA (1) | CA2541402A1 (es) |
CO (1) | CO5690561A2 (es) |
MX (1) | MXPA06003982A (es) |
PA (1) | PA8614901A1 (es) |
PE (1) | PE20050480A1 (es) |
TW (1) | TW200528113A (es) |
WO (1) | WO2005037287A1 (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1863810B (zh) * | 2003-04-09 | 2010-12-01 | 惠氏公司 | [2-(8,9-二氧代-2,6-二氮杂二环[5.2.0]壬-1(7)-烯-2-基)烷基]膦酸衍生物及其作为n-甲基-d-天冬氨酸(nmda)受体拮抗剂的应用 |
CA2521394A1 (en) * | 2003-04-09 | 2004-10-28 | Wyeth | Pharmaceutical compositions for intranasal administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.o]non-1 (7)-en-2-yl)alkyl] phosphonic acid and derivatives and methods of use thereof |
GT200400213A (es) * | 2003-10-22 | 2007-09-05 | Metodos para la preparacion del acido {2-[(8,9)-dioxo-2,6-diaza-biciclo[5.2.0]-non-1(7)-en-2-il]etil} fosfonico y esteres del mismo | |
US20050244365A1 (en) * | 2004-05-03 | 2005-11-03 | Novaflux Biosciences, Inc. | Methods, compositions, formulations, and uses of cellulose and acrylic-based polymers |
CN101155579B (zh) | 2005-02-03 | 2012-10-31 | 综合医院公司 | 治疗吉非替尼耐药性癌症的方法 |
CN103110948A (zh) | 2005-11-04 | 2013-05-22 | 惠氏公司 | mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合 |
EP2195031A1 (en) * | 2007-08-27 | 2010-06-16 | Wyeth a Corporation of the State of Delaware | Compositions and methods employing nmda antagonists for achieving an anesthetic-sparing effect |
US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
KR20100121483A (ko) | 2008-02-11 | 2010-11-17 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 용출성이 개선된 정제 |
KR20130088908A (ko) | 2008-06-17 | 2013-08-08 | 와이어쓰 엘엘씨 | Hki-272 및 비노렐빈을 함유하는 항신생물성 조합물 |
CN109464445A (zh) | 2008-08-04 | 2019-03-15 | 惠氏有限责任公司 | 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合 |
US8771735B2 (en) * | 2008-11-04 | 2014-07-08 | Jazz Pharmaceuticals, Inc. | Immediate release dosage forms of sodium oxybate |
US8778398B2 (en) | 2008-11-04 | 2014-07-15 | Jazz Pharmaceuticals, Inc. | Immediate release formulations and dosage forms of gamma-hydroxybutyrate |
ES2941894T3 (es) | 2009-04-06 | 2023-05-26 | Wyeth Llc | Régimen de tratamiento que utiliza neratinib contra el cáncer de mama |
CA2780332C (en) | 2009-11-09 | 2018-01-30 | Wyeth Llc | Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea |
PT2498756T (pt) * | 2009-11-09 | 2019-11-26 | Wyeth Llc | Formulações de comprimidos de maleato de neratinib |
MX2020011961A (es) | 2010-03-24 | 2022-04-19 | Jazz Pharmaceuticals Inc | Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas. |
US10398662B1 (en) | 2015-02-18 | 2019-09-03 | Jazz Pharma Ireland Limited | GHB formulation and method for its manufacture |
US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
US20180263936A1 (en) | 2017-03-17 | 2018-09-20 | Jazz Pharmaceuticals Ireland Limited | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
CN113395960A (zh) | 2018-11-19 | 2021-09-14 | 爵士制药爱尔兰有限公司 | 抗酒精药物制剂 |
JP2022522270A (ja) | 2019-03-01 | 2022-04-15 | フラメル アイルランド リミテッド | 食事摂取状態における改善された薬物動態を有するガンマ-ヒドロキシ酪酸塩組成物 |
US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5168103A (en) * | 1991-01-22 | 1992-12-01 | American Home Products Corporation | [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives |
US5124319A (en) * | 1991-10-11 | 1992-06-23 | American Home Products Corporation | Benzimidazole phosphono-amino acids |
US5990307A (en) * | 1997-08-01 | 1999-11-23 | American Home Products Corporation | Process for the preparation of [2-((8.9)-Dioxo-2,6-Diazabicyclo [5.2.0]-Non-1(7)-en-2yl) Ethyl]Phosphonic acid |
US6225343B1 (en) * | 1999-06-16 | 2001-05-01 | Nastech Pharmaceutical Company, Inc. | Compositions and methods comprising morphine gluconate |
US6468559B1 (en) * | 2000-04-28 | 2002-10-22 | Lipocine, Inc. | Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods |
US6555581B1 (en) * | 2001-02-15 | 2003-04-29 | Jones Pharma, Inc. | Levothyroxine compositions and methods |
US20020160043A1 (en) * | 2001-02-27 | 2002-10-31 | Dennis Coleman | Compositions and method of manufacture for oral dissolvable dosage forms |
UA78529C2 (en) * | 2001-10-10 | 2007-04-10 | Wyeth Corp | Derivatives of [[2-(amino-3,4-dioxo-1-cyclobutene-1-yl)amino]alkyl] acid for treating pain |
JP4452970B2 (ja) * | 2002-03-27 | 2010-04-21 | 日本臓器製薬株式会社 | ジクロフェナクナトリウム経口製剤 |
US20040082543A1 (en) * | 2002-10-29 | 2004-04-29 | Pharmacia Corporation | Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain |
CA2521394A1 (en) * | 2003-04-09 | 2004-10-28 | Wyeth | Pharmaceutical compositions for intranasal administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.o]non-1 (7)-en-2-yl)alkyl] phosphonic acid and derivatives and methods of use thereof |
-
2004
- 2004-10-08 US US10/961,871 patent/US20050142192A1/en not_active Abandoned
- 2004-10-13 TW TW093131004A patent/TW200528113A/zh unknown
- 2004-10-14 PA PA20048614901A patent/PA8614901A1/es unknown
- 2004-10-14 KR KR1020067007283A patent/KR20070029114A/ko not_active Application Discontinuation
- 2004-10-14 EP EP04795300A patent/EP1682151A1/en not_active Withdrawn
- 2004-10-14 BR BRPI0415432-0A patent/BRPI0415432A/pt not_active IP Right Cessation
- 2004-10-14 CA CA002541402A patent/CA2541402A1/en not_active Abandoned
- 2004-10-14 JP JP2006535354A patent/JP2007509055A/ja active Pending
- 2004-10-14 MX MXPA06003982A patent/MXPA06003982A/es unknown
- 2004-10-14 AU AU2004281806A patent/AU2004281806A1/en not_active Abandoned
- 2004-10-14 WO PCT/US2004/034113 patent/WO2005037287A1/en active Application Filing
- 2004-10-15 PE PE2004001002A patent/PE20050480A1/es not_active Application Discontinuation
-
2006
- 2006-04-19 CO CO06037154A patent/CO5690561A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MXPA06003982A (es) | 2006-07-05 |
BRPI0415432A (pt) | 2006-12-05 |
AU2004281806A1 (en) | 2005-04-28 |
WO2005037287A1 (en) | 2005-04-28 |
TW200528113A (en) | 2005-09-01 |
PE20050480A1 (es) | 2005-10-24 |
JP2007509055A (ja) | 2007-04-12 |
KR20070029114A (ko) | 2007-03-13 |
WO2005037287A8 (en) | 2005-06-30 |
PA8614901A1 (es) | 2006-05-16 |
US20050142192A1 (en) | 2005-06-30 |
CA2541402A1 (en) | 2005-04-28 |
EP1682151A1 (en) | 2006-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5690561A2 (es) | Administracion oral de acido [2-(8,9-dioxo-2,6-diazabiciclo[5.2.0]non-1(7)-en-2-il)alquil]fosfonico y derivados | |
HUP0101511A2 (hu) | 1-[(1-Szubsztituált-4-piperidinil)-metil]-4-piperidin-származékok, eljárás a vegyületek előállítására, a vegyületeket tartalmazó gyógyászati készítmények és intermedierjeik | |
ES2067456T3 (es) | Nuevos derivados de aminoacidos, procedimientos para su preparacion y composicion farmaceutica que los comprende. | |
GB0015876D0 (en) | Organic compounds | |
EA200200417A1 (ru) | Фармацевтически активные производные сульфонамида | |
KR890008155A (ko) | 신규인 유도체, 그 제조방법 및 의약에서의 사용 | |
TR200200099T2 (tr) | Th2 farklılaşma inhibitörleri | |
RU2001122727A (ru) | Амиды кислот, способ их получения и фармацевтическая композиция на их основе | |
ES2061848T3 (es) | Compuestos triciclos, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden. | |
CO5140104A1 (es) | Derivados de mevinolina y preparacion farmaceuticas que los contienen | |
BR0314591A (pt) | Métodos de aumento de plaquetas e produção de célula tronco hematopoiética | |
DK0406119T3 (da) | Hidtil ukendte peptidderivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler indeholdende dem | |
AR012436A1 (es) | Compuestos de 4-aminopirido[2,3-d]pirimidina 5,7-disustituidos, composicion farmaceutica que los comprende, el uso de los mismos para lamanufactura de medicamentos, un procedimiento para su preparacion. | |
EA200300044A1 (ru) | Новые замещенные фталиды, способ их получения и содержащие их фармацевтические композиции | |
EA200100597A3 (ru) | Новые 1,1- и 1,2-дизамещенные циклопропановые соединения, способ их получения и содержащие их фармацевтические композиции | |
EA199800155A1 (ru) | Новое соединение | |
HUP0203275A2 (hu) | 1-(Gyűrűs amino)-alkilciklohexán-származékok, ezeket tartalmazó görcsoldó hatású gyógyszerkészítmények, valamint ezek alkalmazása | |
EA200100969A1 (ru) | Новые соединения циклобутендиона, способ их получения и содержащие их фармацевтические композиции | |
UY24697A1 (es) | Metodos para producir inhibidores de vih-proteasa y productos intermedios para producir inhibidores de vih-proteasa | |
AR027578A1 (es) | Derivados de indano | |
AR027454A1 (es) | Derivados de beta-alanina, utiles como antagonistas de receptores, las composiciones farmaceuticas que las contienen y el uso de los mismos para lapreparacion de medicamentos | |
ATE60787T1 (de) | Pharmakologisch wirksame verbindungen. | |
HRP20050617A2 (en) | Imidazol derivatives having affinity for alpha 2 receptors activity | |
SE8802066D0 (sv) | N-imidazolyl derivatives of bicyclic compounds useful in medicine | |
ES2088567T3 (es) | Empleo de derivados de la 2-iminotioazolidin-4-ona como nuevos productos activos para medicamentos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |